NCT02232178View on ClinicalTrials.gov

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 20, 2014

Primary Completion Date

February 23, 2015

Study Completion Date

March 23, 2015

Conditions
Hernioplasty
Interventions
DRUG

2 100mg Xaracoll implants

DRUG

3 100mg Xaracoll implants

DRUG

150mg Bupivacaine HCl injection

Trial Locations (5)

35660

Shoals Medical Trials, Sheffield

36207

Pinnacle Research Group, Anniston

43210

Wexner Medical Center at Ohio State University, Columbus

77401

First Surgical Hospital, Bellaire

77704

Victory Hospital, Houston

Sponsors

Lead Sponsor

Innocoll
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Innocoll

INDUSTRY

NCT02232178 - Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant | Biotech Hunter | Biotech Hunter